Adrenergic beta-2 Receptor Agonists
"Adrenergic beta-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
| Descriptor ID |
D058666
|
| MeSH Number(s) |
D27.505.519.625.050.100.200.200 D27.505.696.577.050.100.200.200
|
| Concept/Terms |
Adrenergic beta-2 Receptor Agonists- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta 2 Receptor Agonists
- Adrenergic beta2-Agonists
- Adrenergic beta2 Agonists
- beta2-Agonists, Adrenergic
- Adrenergic beta-2 Agonists
- Adrenergic beta 2 Agonists
- Agonists, Adrenergic beta-2
- beta-2 Agonists, Adrenergic
- Adrenergic beta-2 Receptor Agonist
- Adrenergic beta 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic beta-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic beta-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 19 | 8 | 27 |
| 2018 | 29 | 8 | 37 |
| 2019 | 7 | 2 | 9 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic beta-2 Receptor Agonists" by people in Profiles.
-
Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry. PLoS One. 2021; 16(6):e0252576.
-
Statement from the Japanese Respiratory Society: Working diagnosis and initial management of COPD during the COVID-19 pandemic. Respir Investig. 2021 Jul; 59(4):385-388.
-
Impact of the COVID-19 pandemic in children with allergic asthma. J Allergy Clin Immunol Pract. 2020 10; 8(9):3172-3174.e1.
-
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020 May; 58(3):155-168.
-
Case report: Paradoxical responses to short acting beta-agonists in a pediatric patient. J Asthma. 2021 02; 58(2):213-215.
-
A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
-
New asthma treatment recommendations. Lancet Respir Med. 2019 06; 7(6):479.
-
New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Ter Arkh. 2019 Mar 30; 91(3):76-85.
-
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019; 14:531-546.
-
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. Int J Chron Obstruct Pulmon Dis. 2019; 14:479-491.